Good morning. Elizabeth Cooney here in Boston filling in for Ed Silverman on a balmy August morning. Lots to catch up on today:
The Trump administration on Wednesday finalized long-sought rules for when Medicare will cover CAR-T treatments, often curative therapies that harness patients’ own immune cells against their cancer, STAT reports. Medicare will pay for CAR-T therapies even when used to treat conditions that aren’t FDA-approved. The two approved CAR-T treatments on the market are Yescarta from Gilead Sciences (GILD) for non-Hodgkin lymphoma and Kymriah from Novartis (NVS) for acute lymphoblastic leukemia.